Exclusive Networks Appoints Jesper Trolle as CEO
15.9.2020 10:00:00 EEST | Business Wire | Press release
Exclusive Networks (‘Exclusive’) today announced the appointment of Jesper Trolle as CEO with immediate effect. Trolle joins Exclusive from ECS Arrow Electronics, where he is currently President of the Americas, and will be responsible for driving the next phase of growth at the company and upscaling the business. Trolle takes over from Olivier Breittmayer who becomes a non-executive Board member of Exclusive. The move is part of a planned succession strategy and Trolle will work alongside Breittmayer for the next three months to ensure a smooth transition.
Vastly experienced and recognised as an entrepreneurial business leader within the IT industry, Trolle has spent over 28 years working in the sector, initially within the reseller community, before moving into distribution. In 2001 he founded Next Denmark A/S which was acquired by DNS Denmark, which in turn was acquired by Arrow in 2005. Since then, Jesper has held a number of diverse positions in multiple locations within Arrow, seeing rapid success and progression, including stints in Germany running central and eastern Europe, and Paris, running north-west Europe. He took up the role as Arrow’s President Americas in 2017, based out of Denver, Colorado, where he has successfully grown a double-digit $bn business.
Speaking about the appointment, Breittmayer said, “Jesper was the standout choice following an intensive search and selection process these last six months or so. His cultural and international experience, obvious entrepreneurial DNA, knowledge of upscaling global businesses at pace and empathy with value-based distribution is impressive and refreshing. It is with confidence and a smile that we are getting such a capable person to take over the helm of the business we’ve grown by some 2,000% over the last 17 years.”
Talking of his appointment Trolle added, “Opportunities like this do not come around that often, but in distribution, Exclusive is at the top of the list if they do. I’m delighted to be joining such a successful company with a strong reputation for innovation and exceptional growth. Exclusive is renowned for its disruptive approach and relentless focus on value creation for its partners. When given the opportunity to become a part of the Exclusive family and next phase of its journey, it was an easy and fast decision to make.
“Olivier’s vision of creating the only specialist distributor on a global scale, focused on high performance cybersecurity infrastructure, was imaginative and disruptive – and that vision has become reality. Exclusive continues to buck market trends, growing at pace organically, expanding geographically and still disrupting. The only thing that hasn’t changed or been diluted is the obsession with value, services and specialism. This scale and specialist approach has never before been achieved. My job is clear: turn the global presence into a cybersecurity infrastructure powerhouse, at scale and speed, and it is a challenge I relish, feel qualified to do and very much look forward to,” concluded Trolle.
Michail Zekkos, Partner at Permira, and a member of Exclusive’s Board of Directors, commented, “Olivier is a pioneer and a true inspiration in modern day value-based distribution. It was a hard task to find his natural replacement, but in Jesper we feel we have done just that. He’s exceptionally talented and culturally very aligned to L’Esprit Exclusive. Olivier’s vision of building the Exclusive ‘Network’ of value-based distribution businesses, globally guided but locally delivered, was unique.
“The business has consistently outperformed market growth rates; expanded at breathtaking speed and delivered financial results that are exceptional for the sector. This is a great platform from which Jesper can continue the adventure and scale-out the business, and with his vision, multicultural background and experience of growth at scale we feel confident he is more than able to meet the challenge.
“Myself and the rest of the Exclusive family thank Olivier wholeheartedly for his indelible impact on the company, and welcome him onto the Board of Directors.”
Breittmayer added finally, “It’s not goodbye, it’s à plus tard.”
-ends-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005084/en/
Contact information
Exclusive Networks Contact:
Jon Bawden
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
